Search results for "Metas"

showing 10 items of 1693 documents

Lipopolysaccharide‐regulated secretion of soluble and vesicle‐based proteins from a panel of colorectal cancer cell lines

2021

Purpose To mimic the perioperative microenvironment where bacterial products get in contact with colorectal cancer (CRC) cells and study its impact on protein release, we exposed six CRC cell lines to lipopolysaccharide (LPS) and investigated the effect on the secretome using in-depth mass spectrometry-based proteomics. Experimental design Cancer cell secretome was harvested in bio-duplicate after LPS treatment, and separated in EV and soluble secretome (SS) fractions. Gel-fractionated proteins were analysed by label-free nano-liquid chromatography coupled to tandem mass spectrometry. NF-κB activation, triggered upon LPS treatment, was evaluated. Results We report a CRC secretome dataset of…

Lipopolysaccharides0301 basic medicine030102 biochemistry & molecular biologymedicine.diagnostic_testLipopolysaccharideChemistryClinical BiochemistryCellmedicine.diseaseProteomicsMolecular biologyExosomeMetastasis03 medical and health scienceschemistry.chemical_compound030104 developmental biologymedicine.anatomical_structureWestern blotCell cultureCancer cellmedicinePROTEOMICS – Clinical Applications
researchProduct

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression

2008

Abstract Background Hypoxia-inducible factor 1 alpha (HIF-1α) is involved in processes promoting carcinogenesis of many tumors. However, its role in the development of colorectal cancer is unknown. To investigate the significance of HIF-1α during colorectal carcinogenesis and progression we examined its expression in precursor lesions constituting the conventional and serrated pathways, as well as in non-metastatic and metastatic adenocarcinomas. Methods Immunohistochemistry and Western blot is used to analyse HIF-1α expression in normal colonic mucosa, hyperplastic polyps (HPP), sessile serrated adenomas (SSA), low-grade (TA-LGD) and high-grade (TA-HGD) traditional adenomas as well as in n…

LipopolysaccharidesCancer ResearchPathologymedicine.medical_specialtyColorectal cancerColonic PolypsMouse model of colorectal and intestinal cancermedicine.disease_causelcsh:RC254-282chemistry.chemical_compoundWestern blotCell Line TumorGeneticsMedicineHumansNeoplasm Metastasismedicine.diagnostic_testbusiness.industrymedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryVascular endothelial growth factorCell Transformation NeoplasticOncologychemistryHyperplastic PolypTumor progressionDisease ProgressionImmunohistochemistrybusinessCarcinogenesisColorectal NeoplasmsPrecancerous ConditionsResearch ArticleBMC Cancer
researchProduct

Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer.

2007

Signaling mediating colorectal cancer (CRC) progression is incompletely understood. Previously, we identified lipopolysaccharide (LPS), an endotoxin of ubiquitously existing colonic bacteria, as a pivotal stimulus increasing the metastatic potential of human CRC. Since the ubiquitous colonic bacteria release large amounts of LPS this observation could be of enormous relevance for the progression of CRC. In this study we present data contributing to the elucidation of its mode of action. Since both receptors CD14 and TLR4 act as LPS mediators, we determined their expression in various CRC cell lines and in 115 non-metastatic, lymphogenous-metastatic and haematogenous-metastatic CRC specimens…

LipopolysaccharidesColorectal cancerCellLipopolysaccharide ReceptorsBiologyDownregulation and upregulationCell Line TumorGeneticsmedicineHumansNeoplasm MetastasisReceptorFluorescent Antibody Technique IndirectNeoplasm StagingRetrospective StudiesOncogeneCarcinomaGeneral MedicineCell cyclemedicine.diseaseMolecular medicineImmunohistochemistrydigestive system diseasesGene Expression Regulation NeoplasticToll-Like Receptor 4medicine.anatomical_structureLymphatic MetastasisImmunologyTLR4Cancer researchlipids (amino acids peptides and proteins)Caco-2 CellsColorectal NeoplasmsInternational journal of molecular medicine
researchProduct

Age and metasomatic alteration of the Mt Neill Granite at Nooldoonooldoona Waterhole, Mt Painter Inlier, South Australia

2001

Quartz feldspar augen gneisses, quartz augen schists and trondhjemites outcrop at Nooldoonooldoona Waterhole in the southwestern corner of the Proterozoic Mt Painter Inlier, northern Flinders Ranges, South Australia. These rocks were previously interpreted as having different origins and ages. However, we argue that all rock types were the result of deformation and strong metasomatic alteration of one common precursor: the Mt Neill Granite. Our conclusion is based on field observations that show that the different lithologies grade into each other and that intrusive contacts are lacking. Whole rock major and trace element analyses also point to a common protolith. Finally, Pb/Pb dating of m…

LithologyProterozoicGeochronologyEarth and Planetary Sciences (miscellaneous)LithostratigraphyGeochemistrySchistGeneral Earth and Planetary SciencesMetasomatismProtolithGeologyGneissAustralian Journal of Earth Sciences
researchProduct

Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.

1994

Hepatocellular carcinoma is one of the most common human cancers with an annual incidence of about 1,000,000 cases worldwide. Although hepatocellular carcinoma is predominant in hepatitis B virus endemic areas, it has also become a major problem in Europe, Japan and North America in close association with the increasing incidence of hepatitis C virus infection. The pathogenetic role of hepatitis C virus infection in the development of HBsAg-negative hepatocellular carcinoma needs to be clarified. In this paper the case of a 66-year-old HBsAg-negative and anti-HCV positive female who developed hepatocellular carcinoma in a cirrhotic liver is reported. After 1 year of follow up, urgent laparo…

Liver CirrhosisPathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusHepacivirusOvaryHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologyVirusMetastasisFlaviviridaeInternal medicinemedicineHumansAgedHepatitis B virusOvarian NeoplasmsHepatitis B Surface AntigensHepatologybiologyIncidenceLiver Neoplasmsmedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureHepatocellular carcinomaRNA ViralFemaleTomography X-Ray ComputedJournal of hepatology
researchProduct

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.

2012

A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median survival = 27 days) was significantly improved when hyaluronan scaffolds embedded with mesenchimal stem cells (MSC) were implanted in the abdominal area 4 days after SKW6.4 injection (median survival = 39.5 days). Mice implanted with MSC showed a significant improvement of hepatic functionality in lymphoma xenografts, as demonstrated by measurement of serum ALT/AST levels. Co-culture of MSC with lymphoma cells enhanced the release of hepatocyte growth factor (HGF) by MSC…

Liver functionality. Lymphoma-bearing xenograftsPathologymedicine.medical_specialtyTime FactorsCell SurvivalMice NudeCell CommunicationMice SCIDMesenchymal Stem Cell Transplantationlymphoma.Mesenchymal stem cells; hepato-protective; lymphoma.Metastasischemistry.chemical_compoundMicehemic and lymphatic diseasesCell Line Tumorhepato-protectiveHyaluronic acidMedicineAnimalsHumansPharmacology (medical)Aspartate AminotransferasesHyaluronic AcidMesenchymal stem cellPharmacologyMesenchymal stem cells; Liver functionality. Lymphoma-bearing xenograftsTissue Scaffoldsbusiness.industryHepatocyte Growth FactorLymphoblastLymphoma Non-HodgkinMesenchymal stem cellLiver NeoplasmsAlanine TransaminaseMesenchymal Stem Cellsmedicine.diseaseXenograft Model Antitumor AssaysCoculture TechniquesLymphomaOncologychemistryLiverCell cultureHepatocyte growth factorStem cellbusinessBiomarkersmedicine.drugInvestigational new drugs
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

2019

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

Liver metastasemedicine.medical_specialtyPathologySocio-culturale03 medical and health sciencesLiver metastasesRare Diseases0302 clinical medicineLiver metastases ; Neuroendocrine tumours ; Pancreas ; Rare cancersNeuroendocrine tumoursMultidisciplinary approachRare DiseaseNeuroendocrine tumourHumansMedicinePancreaRare cancersPrecision MedicineIntensive care medicinePancreasLiver metastases Neuroendocrine tumours Pancreas Rare cancersPatient Care Teambusiness.industryPancreatic NeoplasmRare cancerGeneral MedicinePancreatic NeoplasmsSurvival RateNeuroendocrine TumorsLiver metastases; Neuroendocrine tumours; Pancreas; Rare cancers; Surgery; OncologyOncology030220 oncology & carcinogenesisMandate030211 gastroenterology & hepatologySurgerybusinessNeuroendocrine TumorDelivery of Health CareHuman
researchProduct

Colorectal cancer-derived small extracellular vesicles induce TGFβ1-mediated epithelial to mesenchymal transition of normal hepatocytes: new insights…

2023

More than 50% of patients affected by colorectal cancer (CRC) present liver metastasis, which is the most frequent cause of CRC-associated death. Numerous studies have shown that metastatic cascade is the result of complex mechanisms based on two-way interactions between invasive CRC cells and liver resident cells. In recent years, several findings have demonstrated that small extracellular vesicles (SEVs) released by cancer cells play a crucial role in the formation of pre-metastatic niche in the liver, specifically affecting the activities of non-parenchymal cells as Kupffer cells and hepatic stellate cells. However, although hepatocytes (heps) are the most conspicuous in the liver, their…

Liver metastasiTransforming growth factor‑β1 (TGFβ1).Small extracellular vesicleHepatocyteColorectal cancer
researchProduct

Indications for Locoregional Tumor Therapies: CRC Liver Metastases

2018

The liver represents the most affected site in patients affected by colorectal carcinoma (mCRC) [1]. More than half cases develop colorectal liver metastases (CLMs) during the evolution of the disease, and about one-quarter occur at the disease onset [1, 2]. To date, the standard treatment of CLM is represented by liver surgery, which has allowed to achieve interesting long-term survival rates (40-60%) [3] in reported series, while it is less than 25% for patients who do not undergo surgery [4]. Unfortunately, most patients (80%), however, are not immediately eligible for surgery [5, 6]. For these patients, surgical treatment may be administered in combination with chemotherapy regimens (+/…

Liver surgerymedicine.medical_specialtyChemotherapySettore MED/06 - Oncologia Medicabusiness.industryColorectal cancermedicine.medical_treatmentStandard treatmentCRC liver metastasesDiseasemedicine.diseaseSurgeryQuality of lifemedicineIn patientbusinessTherapeutic strategy
researchProduct